Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23414888 | 0.84 | FFAR1 (0.74) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL14857496 | 0.84 | FFAR1 (0.78) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL15283661 | 0.83 | FFAR1 (0.67) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL4128208 | 0.82 | FFAR1 (0.71) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL20599451 | 0.82 | FFAR1 (0.70) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL304019 | 0.81 | FFAR1 (1.00) | FFAR1DGAT1LPLLIPGF11 | |
| SCHEMBL14746348 | 0.81 | FFAR1 (0.74) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL9281333 | 0.81 | FFAR1 (0.74) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL23414658 | 0.80 | FFAR1 (0.68) | FFAR1AAK1DGAT1LPLLIPG | |
| SCHEMBL15508014 | 0.80 | FFAR1 (0.58) | FFAR1AAK1LPLLIPGF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644991-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3644991-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210380580-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380580-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3644991-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005588-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005588-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380580-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM4, CHRM3, CHRM5 | FFAR1 498/4885AAK1 643/4885DGAT1 4254/4885 |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM3, CHRM5 | FFAR1 498/4885AAK1 643/4885DGAT1 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.